Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

41.87 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62
Open 41.87
Bid (Size) 41.00 (300)
Ask (Size) 43.73 (200)
Prev. Close 41.87
Today's Range 41.87 - 41.87
52wk Range 28.66 - 91.00
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026
NEW YORK, NY - April 8, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit

Performance

YTD
+9.6%
+9.6%
1 Month
+23.2%
+23.2%
3 Month
+13.2%
+13.2%
6 Month
-52.7%
-52.7%
1 Year
-40.6%
-40.6%

More News

Read More
Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation ↗
Via Chartmill
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORT CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CORT CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
2 Profitable Stocks to Consider Right Now and 1 We Avoid
Via StockStory
News headline image
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights
From Robbins LLP
Via Business Wire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORCEPT THERAPEUTICS DEADLINE: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CORCEPT THERAPEUTICS DEADLINE: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
2 Cash-Heavy Stocks Worth Your Attention and 1 We Find Risky
Via StockStory
News headline image
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
Via MarketMinute
Topics ETFs Intellectual Property Stocks

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 41.87
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 04/08/26 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 4.85B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.